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Discovery of Haptoglobins - Haptoglobins are serum glyco¬ 
proteins capable of binding free hemoglobin in vivo and in vitro. 
The term haptoglobin is derived from the Greek word haptein, "to 
fix or to seize," because it unites with hemoglobin to form a 
stable complex.-^ 
The original investigation of haptoglobinsin the 1940's 
was performed by Jayle and Abdellatif in France. They showed 
conclusively that a particular serum protein was capable of 
O 
binding with hemoglobin and characterized it as a glycoprotein. 
In 1950, Jayle and Badin showed that both haptoglobin and the 
haptoglobin-hemoglobin complex migrated electrophoretically as 
alpha2 proteins.^ In 1952 they demonstrated that haptoglobin 
was responsible for most, if not all, of the increase in alphap 
globulins seen in "pathologic sera The nature of the pathology 
was not specified.^ 
The initial studies of haptoglobin in the United States 
were performed by Tuttle, who, as a member of the Department of 
Pediatrics at the University of Tennessee, was unaware of Jayle's 
work."’ Using filter paper electrophoresis with a veronal buffer, 
pH 8.6, he noted that hemoglobin by itself migrated at the same 
rate as the beta globulin of a serum sample migrating in a separate 
column. When the hemoglobin was mixed with fetal sera in consecutively 
large amounts, successively darker bands appeared in the beta globulin 
area. However, the mixture of hemoglobin with the sera of older 
children and adults yielded quite different electrophoretic results: 
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now the hemoglobin appeared in the alpha2 globulins as one band. 
As successively larger amounts of hemoglobin were added to a 
given amount of serum, the alpha2 band increased in intensity until 
a second band appeared, representing hemoglobin in the beta range. 
From these observations, he concluded that older children and adults 
had a serum protein capable of binding finite amounts of hemoglobin 
not present in infants, and that the complex of serum protein and 
hemoglobin migrated in the alpha2 range. 
Chemistry of Haptoglobin - Although the haptoglobins migrate 
with the alpha2 fraction of serum protein, they have distinctive 
chemical properties oftheir own. They are 20% carbohvdrate - 
specifically sialic acid, fucose, hexoses, and glucosamines - and 
80% protein.6’7 The protein portion consists of two different 
polypeptide chains termed alpha and beta. Every haptoglobin 
molecule has the same amino acid sequence in its beta chain. This 
beta chain binds to the carbohvdrate moietv, and also free hemo- 
O Q 
globin, when it is available, in a ratio of 1 to 1. >7 The carbo¬ 
hydrate itself, however, is not essential to the binding nrocess.7(1 
The alpha chain, in contrast to the beta chain, is not 
identical in every individual, but is subject to genetic variation.' 
Genetics of Haptoglobins - In 1955, Smithies examined the 
electrophoretic distribution of serum proteins of normal adults 
and noted that the sera could easily be classified into three groups 
on the basis of the gel patterns of the proteins in the alnha2 
range. One pattern consisted of a band which had migrated faster 
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than transferrin; a second pattern consisted of a number of bands 
which had migrated more slowly than transferrin; while the third 
pattern consisted of a band migrating more quickly than trans¬ 
ferrin identical to the solitary band of the first type plus a 
number of more slowly migrating bands. It was further demonstrated 
that the proteins of these bands were capable of binding hemoglobin. 
That same year Smithies and Walker postulated from extensive 
family studies that the three serum protein groups were determined 
by a single pair of allelic genes with incomplete dominance. J The 
persons having the serum protein pattern first described above 
were thought to be homozygous for one allele; the individuals with 
the second pattern were thought to be homozygous for the second 
allele, and the individuals with the third pattern were considered 
to be heterozygotes containing both alleles. In 1936, these same 
two scientists proposed the present nomenclature for phenotypes 
and genotypes^: 
Old Phenotype 
Serum Protein Pattern 1 
Serum Protein Pattern 2 






Hp1 / Hp1 
Hp2 / pn2 
Hp1 / Hp2 
The incidence of the various pheotypes has been carefully studied: 
# of Persons 
Study in Study Haptog lob in T' gpe 
Study 1 
1 s 







Study 2 (Prague citizens)^ - 17.1% 35.1% 47.7% 
Study 3 (Maryland citizens)^ 192 12.5% 43.2% 44.2% 
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With the exception of a few rare subtypes of haptoglobins^’^ 
and familial ahaptoglobinemia^5^■> every one can easily be 
classified into one of the three above basic phenotypes. The 
genetic properties of haptoglobins are now widely accepted and 
? 9 
have been used in establishing paternity. 
Synthesis of Haptoglobins - All available evidence points 
to the liver as the site of haptoglobin synthesis. Rat liver 
perfused ini vitro incorporates labeled amino acids into 
haptoglobin.^ In vivo studies in the dog show that amino acid 
incorporation into haptoglobin is abolished by hepatectomy. q 
A rise in haptoglobin levels of parenchymal liver cells produced 
by turpentine injections is abolished if the animal is previously 
damaged by the administration of carbon tetrachloride.*-n mari 
parenchymal liver damage is accompanied by low serum haptoglobin 
levels. ° A most conclusive bit of evidence is a recent observation 
of a change in serum haptoglobin phenotype following human liver 
O ~j 
transplantation. ' 
The role of the adrenals in the production of haptoglobin 
is uncertain. They appear to have a permissive effect on the rise 
in serum haptoglobins seen in inflammation: adrenalectomy impairs 
O O 
the rise in haptoglobin levels, ' Haptoglobin levels are significantly 
higher in men than in women, possibly due to the higher androgen 
production in man. 
Clearance, Degradation and Turnover Rate of Haptoglobins - 
Both haptoglobin bound to hemoglobin and presumably free haptoglobin 
are removed from the blood by the reticulo-endothelial system, 
although the rate of removal of bound haptoglobin is much faster 
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than the rate of removal of free haptoglobin. The rate of clearance 
of haptoglobin under normal condition is not vet known, but after 
experimental intravenous administration of free hemoglobin, hapto¬ 
globin is cleared from the plasma at a rate of 15 mg. hemoglobin 
binding capacity per 100 ml. of serum. 
Degradation of haptoglobin and haptoglobin-hemoglobin occurs 
within the reticulo-endothelial (RE) cells. An enzyme has been 
discovered in RE cells which specifically attacks the complex of 
hemoglobin and haptoglobin at the heme moiety: heme 2-methenyl oxvgenase 
The combination of haptoglobin-hemoglobin is too large to be 
filtered by the glomerulus, and under normal condition neither hapto¬ 
globin nor hemoglobin appears in the urine. However, after the 
hemoglobin binding capacity of the serum has been exceeded, free 
hemoglobin will be cleared both by the kidney and by the RE system, 
and will appear in the urine.^ 
When free hemoglobin is released into the intravascular 
compartment, the hemoglobin is bound within a matter of minutes 
and the complex is taken up by the reticuloendothelial system at 
greatly increased rates, but the synthesis of new haptoglobin is 
slow. Consequently, the serum haptoglobin falls to very low levels, 
often to 0, within a matter of hours and remains low for several 
days following hemolysis, a fact of diagnostic importance.^ 
Abnormal Quantities of Haptoglobins - the normal serum 
haptoglobin level ranges from low values of 20 to 50 mg.% hemoglobin 
binding capacity to high values of 150-190 mg.%. These vary with 
the type of haptoglobin.^ 
Haptoglobin levels are markedly lowered in hemolytic 
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conditions, liver disease and pernicious anemia. Haptoglobins 
are absent in intravascular hemolysis because free hemoglobin 
quickly combines with haptoglobin and the complex is quickly 
q r o C. 
taken up by the reticulo-endothelial system. J5The low levels 
in liver disease are the result of decreased synthesis due to 
tired cellular metabolism.^^^ The mechanism of decreased 
40 
imp a] 
haptoglobin levels in pernicious anemia is unclear. 
Haptoglobin levels are elevated in other situations: acute 
and chronic infections,^^^^ burns, trauma?^ collagen disease, 
46,47,48 scurVy} amyloidosis, biliary obstruction, renal disease, 
1 6 49 
Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma. ’ 5 
Haptoglobins are also elevated by the administration of androcens, 
glucocorticoids, parathormone and the purified enzymes papain, 
elastase and hyaluronidase . ^ 
The effect of surgery on haptoglobin levels is controversial. 
Crockson reported a definite rise in serum haptoglobin in most 
patients following surgery, but the rise was extremely variable 
(25 - 100)mg.% and in some patients the hemoglobin level actually 
50,51 
decreased- More recently, Drak in Poland analyzed the 
haptoglobin levels of 40 male patients following surgery. In 
patients who had no local inflammatory or generalized systemic 
reactions, a significant drop in haptoglobin levels from 125 - 
28 mg.% to 82 i 26 mg.% occurred during the first few days and 
persisted 14 to 16 days later. In patients with distinct 
l ocal or systemic reactions postoperatively, haptoglobin levels 
rose sharply the day after the inflammation was noted to a peak 
level of 195 - 45 mg.%. then fell back to the normal starting 
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levels within 14 to 16 days postoperativelv. Patients with febrile 
reactions had rises to significantly higher levels than the levels 
of non-febrile patients. Drak concluded that without comDlicatlons, 
surgery caused a decrease in haptoglobins and hypothetically 
attributed this decrease to "trace hemolysis caused by the crushing 
of blood filled tissues" by surgical manipulation. 
Compatible blood transfusions have no predictable effect on 
haptoglobin levels; they may cause either an increase or a decrease. 
However, an incompatible blood transfusion with hemolysis will 
of course reduce the haptoglobin level to zero. 
Haptoglobins are also related to age: they are absent or 
consistently low during the first two months of life; to sex: they 
are slightly higher in men; and to pregnancy: they are elevated in 
puerperal women.^’^ 
Clinical applications of the measurement of haptoglobins 
are presently: 1) to diagnose hemolytic transfusion reactions; 
2) to diagnose hemolytic anemia,e.gin sickle crisis, in leukemia, 
and other acquired hemolytic anemias; 3) to determine hereditary 
haptoglobin deficiency;4) to aid in the differential diagnosis 
of jaundice; 5) to assess the degree of hepatocellular damage and 
1 35 36 
to prognosticate in patients with cirrhosis and hepatitis. ’ ’ 
Haptoglobins and Cancer - Attempts to Associate Serum 
Haptoglobin Phenotype and Cancer Type - In early studies, Keviatoski 
found no significant difference between the distribution of types 
of haptoglobins in patients with carcinomas of the breast, skin, 
uterus and lips and the distribution among the control popu¬ 




later found that a leukemic population of 79 individuals contained 
an excess of individuals with tvpe 1-1 and a deficiency of 
individuals with type 2-2 when compared, to the inidviduals of the 
control population.^ The relative risk of having leukemia (acute 
lymphocytic, chronic myelogenous or acute myelogenous) among people 
with type 1-1 as compared with people of 2-2 type was approximately 
fourfold. The conclusion held true for subgroups of people 
with each type of leukemia, as well as for the group of leukemic 
patients as a whole (.02 < p < .05). 
Subsequently, Larkin typed 526 cancerous patients with two 
interesting results. First, not only in the leukemias, but also 
in the reticuloses group as a whole (consisting of 36 patients 
suffering from leukemia, myeloma, Hodgkin's disease, or _lympho- 
sarcoma), there was an increased tendency toward a high frequency 
of the gene IIpl and phenotype 1-1. Secondly, 53 females with 
genital cancers showed a considerably lower frequency of the Hpl 
gene than the controls (0.264 for patients vs. 0.388 for controls); 
thus women with genital cancers showed a nreference for type 2-2 
haptoglobins. This group of patients contained 9 with cancer of 
the ovarv, not further specified. 
Haptoglobin Type 1-1 2-1 2-2 
Number of Patients 027 
Larkin's findings concerning female genital cancer were 
not corroborated by a subsequent investigation in 1969. J Mulinicove, 

-9- 
Jandova, and Skoda studied 291 females in Prague with genital 
malignancies and found no relation between the distribution of 
haptoglobin types in either the entire group of 291 patients 
with genital cancers or the 50 patients with carcinoma of the 
ovary, not further specified, and the distribution of haptoglobin 
types in the control population. 
Attempts to Associate Serum Haptoglobin Level and the 
Existence of Malignancy - Cancer in General - In 1956, Jayle, 
Serpicelli, and Robert studied 37 patients with cancer, not further 
specified, whose haptoglobin levels ranged from 60-540 mg.%. 
They concluded that cancer could result in either a normal or a 
high haptoglobin.^ in a 1959 study of 127 Scandinavian patients, 
? f) 
Nyman reached the following conclusions: 
1) In localized cancer, even when complicated by infection, 
the serum haptoglobin level is onlv slightly raised. 
2) In cancer with widespread metastases, haptoglobin levels 
may be high, normal or low. 
3) High haptoglobin levels are most common in patients with 
skeletal and lung lesions and in patients with fever; 
normal values are most often seen in patients with liver 
metastases and with cancer of the mammary glands. 
His study contained two patients with cancer of the ovary, both with 
widespread metastases. One had a level greater than 190 mg.%; the 
other had a level below 190 mg.%. In summary, Nyman found that 
high haptoglobin levels may be of some very limited value in 
determining the location of the cancer, but are of no use in 
determining the amount of tumor. 
Reticuloses - In 1964 Owen found haptoglobin levels 
of patients with lymphomas * leukemias, Hodgkin’s, and mveloma to be 
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significantly higher than that of controls 60 
Mean Hemoglobin Standard Actual 
Binding Capacity Deviation Range 
64 reticulosis patients 147 mg.% 
152 controls 93 mg.% 
91 mg.% 10-420 mg.% 
40 mg.% 10-220 mg.% 
Malpas, in a series of 78 patients with reticuloses, likewise 
noted high serum haptoglobins. He also demonstrated elevations 
in ceruloplasmin, another alpha2 globulin, as well as elevations in 
the alpha2 globulins as a whole.^ However, the rise in alpha2 
globulin could not be correlated with an increased amount of 
haptoglobin or ceruloplasmin. Consequently, the rise in alpha2 
globulins must have been caused by several components, not merely 
haptoglobin or ceruloplasmin; and conversely, an elevated haDto- 
globin or ceruloplasmin level was not necessarily manifested by 
a rise in alpha2 globulins. 
Carcinomas - Owen also noted a rise in haptoglobin 
levels in patients with carcinomas.^ 
Mean Hemoglobin Standard Actual 
Binding Capacity Deviation Range 
54 cancer patients 216 mg.% 
(not further specified) 
152 controls 93 mg.% 
93 mg.% 62-510 mg.% 
40 mg.% 10-220 mg.% 
Of recent interest is a report of fever, refractory anemia, 
and hvperhaptoglobinemia in two patients which were later found 
to have renal cell carcinomasNephrectomy corrected these 
abnormalities. The haptoglobin level of the first patient fell 
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from 435 mg.% preoperatively to 310mg.% on the 14th postoperative 
day, to 80 mg.% 6 months postoperatively. The haptoglobin level 
of the second patient fell from 286 mg.% preoperatively to 111 mg.% 
on the 4th postoperative day. 
Changes in hemoglobin binding capacity may be an accurate 
indication of the affect of radiotherapy on carcinoma of the cervix. 
Stages II and III. ^ The average haptoglobin level of 8 Datients 
with Stage I disease was found to be normal prior to radiotherapy 
and throughout a course of treatment. The average haptoglobin level 
of eight patients with Stage II disease and eight patients with 
Stage III disease was high(234tfig%)before the onset of radiotherapy. 
The onset of radiotherapy was accompanied by a slight rise in 
the average haptoglobin level, followed by a decrease to a normal 
haptoglobin level at 6 months with successful treatment and no 
signs of tumor recurrence. In two patients who had recurrences 
of tumor at notime did the haptoglobin decline to a normal level; and 
at the time of recurrence, haptoglobins in these two patients rose 
to astronomical levels. 
Haptoglobin Turnover Rate and Cancer - Turnover rate 
has been calculated vising I^i _ labeled human haptoglobin in 
control persons and in eight patients with malignant: neoplasms 
31 32 
whose haptoglobin concentrations ranged from 42 mg.% to 702 mg.4. ’ 
In spite of this wide range of concentrations, the turnover rate 
and the half-life of haptoglobin remained relatively constant; T 1/2 
varied from 2.0 to 3.0 days. The constant half-life indicates that 
high haptoglobin levels are not caused by a decreased rate of 
removal of haptoglobin from serum . 
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The turnover rate of haptoglobin in cancer patients 




p. 13, lines 11-12 
2) tumor mass less than 6 cm, 






a tissue diagnosis of the tumor with microscopic examination was 
obtained. Evidence of tumor by physical or surgical examination 
and roentgenology at the time of the sample was noted. On the 
basis of existing evidence patients were classified into three 
groups depending on the amount of tumor they contained: 1) no 
tumor, 2) tumor mass larger than 6 cm. in diameter, 3) tumor 
mass smaller than 6 cm. in diameter. Patients with numerous 
widespread metastases were placed in the third category. Patients 
were also classified according to the three major forms of treat¬ 
ment administered to them before the serum haptoglobin sample was 
drawn: surgery, radiotherapy and chemotherapy, within 0-2 months, 
2 months to 1 year, or 1 year to 5 years nrior to the sample. 
Surgery was laporotomy with total resection, partial resection 
or, if the tumor could not be resected, tumor biopsy. Surgerv was 
followed by radio-and/or chemo-therany. Radiotheany consisted of 
3,000 rads to the pelvis with or without an additional 2,000 rads to 
the abdomen. Chemotherapy was one of three types." 
1) 5 Fluorouracil 7.5 mg./kg., I.V./o.d. x 5d./rno. and 
Uracil mustard 1 mg. p.o./o.d. 
2) Leukeran 4 mg. p.o. o.d. and Velban 0.01 mg./kg. I.V. 
q. 2 wks. 
9 
3) 1,3-Bischloronitrosourea 100 mg./mz l.V..on 2 successive 
days 4-6 - wks . apart,-. 
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In the nonserial studies, to avoid biasing results in patients T-7ith 
serial haptoglobin determinations? onlv the initial serum sample 
was used. Thirty-five patients were followed with serial hapto¬ 
globin determination for periods of up to one vear. In the 
patients who were followed serially, tumor mass size, surgery, 
radio- and chemo-therapy, intercurrent infections, blood trans¬ 
fusions and paracentesis were noted. 
The average age of the ovarian cancer patients was 51.9 
years with a standard deviation of 14 years and an actual range 
of 18 years to 84 years. 
Controls - There were two control groups: a preliminary 
control group (D-Controls) of thirty hospital personnel - nurses, 
doctors and medical students who were in good health with no 
known illnesses ; and a second control group (C-Controls) more 
closely approximating the target population in sex and age: 50 
women admitted to Yale-New Haven Hospital for elective surgery 
with no signs of active inflammation or malignancy. The average 
age of the C-Controls was 43.7 years with a standard deviation of 
12 years and an actual range of 23 to 72 years. Comparisons 
between patients and controls were always comparisons between 
patients and C-Controls. 
Serum Samples - Blood was collected in a lOcc. tube without 
anticoagulant, allowed to stand for one hour, then centrifuged. 
The serum was extracted by pipette, then fresh frozen at -15°C. 
until use. 
Methods of Typing Haptoglobin - All methods for typing 
haptoglobins involve separation of serum components by gel 
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electrophoresis, followed by examination of the distribution of 
bands in the alphao range to determine the type of haptoglobin. 
Type 1-1 contains only one band, but types 2-1 and 2-2 contain 
multiple bands due to various polymer linkages in between the 
6 4 
haptoglobin beta and haptoglobin alpha2 chains. 
The original studies utilized starch gels stained with a 
13 63 
non-specific protein stain amidohlack. ' ’ a new more elegant 
method utilizes polyacrylamide gels stained to reveal only the 
haptoglobin.There is no stain which is specific for haptoglobin, 
but there is a stain specific for the peropidase activity of hemo¬ 
globin. Free hemoglobin added in excess to serum combines with 
haptoglobin readily but changes its electrophoretic mobility only 
slightly. Gel electrophoresis of serum to which hemoglobin has 
been added in excess separates the free hemoglobin and the various 
polymers of haptoglobin bound to hemoglobin. Staining with 
ortho-dianisidine, specific for peroxide activity, reveals the 
band of free hemoglobin and the various bands of haptoglobin 
polymers containing hemoglobin. 
Preparation of Specimens - A freshlv prepared hemolysate 
of adult human hemoglobin A was diluted to a final concentration 
10 mg. per 100 ml. 0.01 ml. of hemoglobin hemolysate was added 
to 0.25 ml. of serum and the mixture was incubated in a water bath 
at 30° C. for 30 min. 
Electrophoresis - Electrophoresis was performed with 
an E-C Apparatus electrophoresis cell using a 7% polyacrylamide 
gel and a Tris ethylenediaminotetraacetic acid (EDTA) - boric 
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acid buffer, pH 8.3 to 8.4. After the gel was formed, 10 lambda 
of complexed serum were inoculated into each slot with a micropipet. 
The samples were allowed to settle in the slots for 5 minutes, and 
electrophoresis was then carried out at 200 volts for 3 hours at 
8° C. 
Staining - Following electrophoresis, the gel slab 
was submerged in o-diansidine solution buffered to pH 4.7 with 
acetate and agitated on a shaker table for thirty minutes. The 
gels developed a cloudy color which was cleared by soaking 
them f°r 30 minutes in an acetate buffer solution. The details 
of the above three steps are reported in the Ferris article.^3 
A picture of a typical gel with haptoglobin types is seen in 
Figure I. 
Method of Determination of Hemoglobin-Binding Capacity - 
Serum haptoglobin concentrations are not reported in mg„ of 
haptoglobin per 100 ml. of serum but in mg. of free hemoglobin 
bound to haptoglobin per 100 ml. of serum. There are four basic 
methods of quantifying haptoglobins: 1) electrophoretic techniques 
15,66,67,68,69^ y) spectrophotometric techniques,'7® 3) immuno 
diffusion,^ anc[ 4) gel f iltration^ ^ ? 73,74 ^ 
Quantitation of a Standard Serum by Electrophoretic 
Techniques - The original concentration of the hemoglobin i.n the 
hemoglobin serum mixture prepared above to type hemoglobin is 
385 mg./lOO ml. By running the gel slab containing the stained 
hemoglobin and separate hemoglobin-haptoglobin bands through a 
densimeter, one can calculate the proportion of free and bound 






Rands of Hemoglobin- 
Haptoglobin 
Rand of Free Hemoglobin 
1 2 3 45678 
1. Type 1-1 
2. Type 2-1 
3. Type 2-2 
4. Type 2-1 
5. Absent Haptoglobin 
6. Type 2-1 
7. Type 2-1 
8. Type 2-2 
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can easily be computed. In this manner the hemoglobin binding 
capacity of patient X-69 was found to be 277 mg. hemoglobin 
binding capacity/100 ml. serum. 
However, in practice, the initial band types 1-1 and 2-1 of 
the gels was quite close to the band of the free hemoglobin band, 
sometimes merging with it prohibiting proper use of the densimeter 
to demonstrate the densities of the separate bands. In addition, 
densimeter and integration procedures were time-consuming and 
cumbersome. Accordingly, an alternate method of quantifying 
haptoglobins was chosen: the spectophotometric method of Tarukoski. '7,) 
Quantitation of Serum Samples by Ppectophotometric 
Techniques with a Standard Serum - The method used was a very 
simple colorimetric reaction which, unlike all other methods of 
quantification did not require either the separation of free 
hemoglobin from bound hemoglobin or the use of special apparatus. 
The final color could be read by any photometer with a light source 
of 395 my • 
An excess of hemoglobin was again added to the serum and 
then o-dianisidine and ethyl hydrogen peroxide were added to give 
a colorimetric reaction. The order and the timing of adding the 
reagents, adjustments in pH, and selection of wave length used in 
the photometer were such that the color produced by the reaction 
between free hemoglobin and the reagents was negligible, while 
the reaction between hemoglobin bound to haptoglobin and the 
reagents was maximal. Thus, this quantitation procedure had an 
additional advantage over other quantitation procedures: prior 
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trace hemolysis of the serum samples with binding; of hapto¬ 
globin and hemoglobin did not affect the results. A standard curve 
was constructed using the spectrophotometric readings of dilutions 
of a .5 ml. aliquot of the standard sera whose full strength hemo¬ 
globin combinding capacity was known to be 277mg.%. The spectro- 
photometric readings of the unknown sera could easily be translated 
in hemoglobin binding capacity using the standard curve. (See 
Figure II). 
Reagents - 1) o-Diansidine reagent - The 
reagent is prepared by dissolving Ig. o-Dianisidine, 0.5g. EDTA 
and 15.6g. (0.1 mole) of NaF^PO^^I^O in one liter of distilled 
water overnight, the unidssolved residue filtered off and the 
solution carefully adjusted to pH 4.10± .05 with two to four drops 
of concentrated H^po^. The reagent is stable for two weeks when 
stored at room temperature, and may be used for several more weeks 
if traces of undissolved precipitate resulting from auto-oxidation 
are filtered off before use. 2) Et.hvlhvdroperoxide, 0.03N - 10 
per cent aquaeous stock solution (3.ON)* is diluted 100 times 
with distilled water. The reagent is stable for months when stored 
in a refrigerator. 3) Hemoglobin A Stock Solution - Centrifuge, 
whole blood. Remove plasma. Wash the red blood cells three times 
with plasma. Remove supernate and record volume of packed cells. 
For each 1 ml. of packed cells add 1.4 ml. distilled water and 
4 ml. of toluene. Shake vigorously for 5 minutes. Centrifuge 
for 15 minutes at 3,000 RPM. Remove top toluene layer by pipette; 
Supplied by Dr. Halbren, Polysciences Corporation Research 





































































































then remove hemoglobin solution by inserting a pipette below the 
plug of capillary material. Filter the solution through Whatman 
42 Filter Paper. Filtrate should be clear. Determine hemoglobin 
content of filtrate. If greater than .10 mg.%, dilute to 10 mg.%. 
Freeze in 5 ml. aliquots. 
Standard Estimation Procedure - Thaw serum 
samples to be analyzed, one 0.5 ml. aliquot of standard serum, 
and one ampule of stock hemoglobin solution* Dilute stock solution 
of hemoglobin and dilute to 60 mg./lOO ml. Prepare dilutions of 
standard serum 1/2, 1/4, l/g and 1/L6 of undiluted concentration, 
leaving at least 0.1 ml. of serum undiluted. Add 0.1 ml. of 
standard serum or diluted standard serum into a small test tube 
containing 0.5 ml. of dilute hemoglobin. Prepare serum samples 
by pipetting 0.1 ml. of serum and 0.1 ml. of water into a small 
test tube containing 1.0 ml. of dilute hemoglobin solution. Mix. 
Pipette 20 lambda of solution of standard sera or unknown sera 
prepared above into a 15 ml. test tube containing 5.0 ml. diansi- 
dine solution. Mix. Let sit for 15 minutes. Add 1.0 ml. of 0.1% 
aqueous ethylhydroperoxide to each large test tube. Mix. Let 
sit for 1 hour. Add 3 drops concentrated phosphoric acid to 
each tube. Mix. Add 6 ml. of distilled water to each tube. Mix. 
Prepare blank solution by adding, 20 lambda of hemoglobin to 11.0 
ml. distilled water. Read smaples in spectrophotometer at 395 
millimicrons, using visible light source. Concentrations of 
unknown sera prepared in this manner and read from standard 
curve are 1/2 the concentrations of the original undiluted sera. 
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Therefore, the concentration from the curve must be doubled to 
obtain the true hemoglobin binding capacity. Should the 
concentration of the unknown sera diluted to 1/2 the original 
concentration be greater than 277 me,. 7, hemoglobin binding 
capacity, the serum must be further diluted so that the reading 
will fall on the standard curve. (This final procedure was not 




Distribution of Haptoglobin Types - The following tables 
state the distribution of haptoglobin tvpes in control ponulations, 
in patients with malignant ovarian tumors and in patients with 
particular types of malignant ovarian tumors. 
Distribution of Haptoglobin Types in Control 
Populations: 
# Type % Tvpe # Type % Type # Type % Tym 
Control Pops. Total # 2 -1 2-1 2-2 2-2 1 -1 1 -1 
D-controls 30 13 43.3 7 23.3 10 33.3 
C-controls 50 26 52.0 19 38.0 5 10.0 
Controls of 
Ferris Study^ 182 83 45.6 69 37.9 30 16.5 
Distribution of Haptoglobin Types in Patients with 
Malignant Ovari an Tumors vs. Distributi on of Haptoglobin Tvpes in 
Controls: 
Patients 58 31 53.4 22 39.9 5 8.6 
C-Controls 50 26 52.0 19 38.0 5 10.0 
x2r?i = -07 P > .70 
Distribution of Haptoglobin Tvpes in Cancer Patients 
Subgrouped by Tumor Type vs. Types of Controls: 
Granulosa-thecal 
cell 2 2 (100) 
Malignant teratoma 1 1 (100) 
Embryonal cell 2 1 (50.0) 1 (50.0) 
Adenocarcinoma 52 27 51.9 20 38.5 5 9.6 
C-Controls 50 26 52.0 19 38.0 5 10.0 
x2 
(2) ~ *00 f otp ■ adenocarcinomas p > . 95 
Distribution of Haptoglobin Types in Patients with 
Dif f erentiated Carcinomas vs Undifferentiated Carcinomas: 
Anaplastic 16 8 50.0 6 37.5 2 12.5 
Differentiated 36 19 52.7 14 38.9 3 8.3 
X2(2) = -12 P > .70 
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Distribution of Haptoglobin Types In Patients with 




















p > .50 
3 
24 
50.0 2 33.3 




Results of Single Determinations of Han tog, lob in Levels - 
Haptoglobin levels in patients with ovarian tumors are related to 
the amount of tumor , type of tumor •, degree of differentiation in 
tumor and to the death of the patient: 
TYPE 2-1 TYPE 2-2 TYPE 1-1 
Mean Mean Mean 
Control Pops. Mean S.D. +2?.D. Mean S.D . +2S.D. Mean S .D. +2S.D. 
D-controls 92 41 10-174 82 44 0-170 66 33 0-132 
C-controls 76 31 14-138 83 53 0-189 96 18 50-132 
Controls of 
Ferris Study-*-J108 36 36-180 83 32 19-147 124 34 58-194 
The C-controls are the actual controls of the experiment. Consid- 
ing the range of normal to be the mean ±2 ! standard deviati on units, 
the upper limit of normal for all types of haptoglobin is 189rog.%. 
Haptoglobin levels of 190mg.% and above were considered grosslv 
elevated, while haptoglobin levels below 190mg.% were considered 
grosslv normal. 
Haptoglobin levels above and below 190mg.% of controls 
and patients subdivided according to amount of tumor and haptoglobin 
levels of patients who died of tumor within two months of determin¬ 
ation are noted. See Figure III. 
In patients with widespread tumor, haptoglobin levels are 
related to histologic, type, to degree of differentiation of tumor, 
and to mucin production by tumor. 
Haptoglobin Levels vs Type of Ovarian Carcinoma in Patients 
With Widespread Tumor: 
// of Average 
TYPe Patients Hp Level mg. % Hp Level 
Granulosa-thecal cell 1 
Malignant teratoma 1 














































































































































































- X JA 
u ^ 
cu 
£ U 4J 
Cfi W CO 
























r—| 1—1 rH CN] ^r 00 co 
P OJ 











































w 0) 4-J p 4-J 
i—i 1—f Cl o p. 
o o £ 
p p C p c 
4-1 4-J cd 4-1 cd 
c p •H •H 
o o H o p 
CJ CJ cd c to 
1 1 > > 
o Q 6 c 
o LO X) 
04 T-1 
CJ 
p H o 
01 (D M-4 4-4 *H 
4-1 4-J o O 4-» 
0) <D cd a g X e c 
co cd <u o *H 
*H •H •H g g 
X X XI X H 
4-J CNj CL) 
• 0 o 4-J 
g £ g X a CU 
a a 3 X 
NO 
° X 
CO NO CO 4-J - 
4-J 4-J *H CL 









Haptoglobin Levels vs Degree of Differentiation in Patients 
With Widespread Adenocarcinoma: 
No. of 
Patients 
Su"i of Average Fp . 
Ranks Level mg. % 
Undifferentiated 
adenocarcinoma 10 132 271 
Differentiated 
adenocarcinoma 19 - 264 
x’= 168 
p > .05 by Wilcoxson Rank Sum Test"7” 
Haptoglobin Levels vs Mucin or Lack of Mucin Producing 




Mucin producing 2 272;380 





In patients with widespread ovarian malignancv, hantoglobin 
levels are related to surgery, radiotherapv or chemotherapy within 
two months prior to obtaining the sample. 
No. of Sum of 
Patients Ranks 
Lap. in last 2 mo. 13 
No Lap. in last 2 mo. 21 
170.5 
r' = 284.5 
.01 <p < .05 bv Wilcoxson Rank Sum Test 
Radio.in last 2 mo. 5 80.5 
No Radio in last 2 mo. 29 - 
x' = 94.5 
p>.05 by Wilsoxson Rank Sum Test 
Chemo. in last 2 mo. 17 336 









x' = 259 
p>.05 by Wilcoxson Rank Sum Test 
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Results of Serial Determinations of Haptoglobin Levels 
No. of 
Group A Patients 
Patients who had a marked decrease of tumor from 
> 6 cm. to < 6 cm. because of tumor therapy and 
whose haptoglobin level decreased from abnormally 
high values to normal ones: X~9, X-25, X-44, X-34, 
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Patients who continued to have or who developed wide¬ 
spread tumor and whose haptoglobin levels remained 
high or rose from normal to high values: X-15, X-20, 
X-32, X-33, X-55, X-31, X-45, X-39, X-62, X-42, X-47, 
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Group C Patients 
Patients with former ovarian malignancies who had 
evidence of either no tumor or tumor < 6 cm. 
during serial studies and who continued to have 
normal haptoglobin levels: X-23, X-27, X-16, X-37, 
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Group D Patients 
Patients in whom haptoglobin levels did not consistently 
correlate with the amount of tumor: 
1) Widespread tumor with consistently low 
haptoglobins: X-18, X-19 2 
2) Patients with widespread tumor who had 
elevated haptoglobins at the time of wide¬ 
spread disease, but had a normal haptoglobin 
level on one or two occasions: X-22, X-35 2 
3) One patient with no present evidence of 
tumor whose haptoglobin level rose: X-53 1 
4) One patient whose haptoglobin level was 
elevated long before there was anv physical 
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Summary of Results of Serial Haptoglobin Determination - 
No. of 
Group 1 Patients 
Patients whose haptoglobin levels rose from normal 
to high levels at the same time as or shortly 
after evidence for tumor mass increasing to > 6cm. 
was discovered: X-20, X-32, X-45, X-39, X-19, X-22. 6 
Group 2 
Patients whose haptoglobin levels rose from normal 
to high before evidence of recurrence of tumor 
mass: X-15, X-35, X-13. 3 
Group 3 
Patients who persistently had tumor mass > 6 cm, 
and who had elevated haptoglobin continuously: 
X-33, X-55, X-31, X-62, X-42, X-47, X-64, X-57, X-70. 9 
Group 4 
Patients of Groups 1 and 2 who had tumor mass 
> 6 cm. of and had elevated haptoglobins for 
most of the time studied but who had a transient decrease 
or a decrease to normal haptoglobin level on one 
or two occasions: X-32, X-22, X-35 3 
Group 5 
Patients of Groups 1 and 2 who had tumor mass > 6 6m, 
and who had elevated haptoglobin on at least one 
occasion but who for most of the time had grosslv 
normal haptoglobin levels: X-19. 1 
Group 6 
Patients who had tumor > 6 cm. but at no time developed 
an elevated haptoglobin level: X-18. 1 
Group 7 
Patients whose haptoglobin level decreased from 
high to normal at the same time as or shortly 
following evidence that tumor mass had decreased 
from widespread disease to estimated tumor mass 




Group 8 Patients 
Patients whose haptoglobin levels decreased from 
high to normal prior to evidence that tumor mass 
had decreased from widespread disease to estimated 
tumor mass < 6 cm. in diameter: X-25, X~46. 
Group 9 
Patients who had < 6 cm. tumor at all times and 
persistently low haptoglobin levels: X-23, X-27, 
X-36, X-16, X-50, X-61, X-58, X-65. 8 
Grouu 10 
Patients who had < 6 cm. tumor at all times and 
persistently high haptoglobins: 0 
Group 11 
Patients who had < 6 cm. tumor and had a high 
haptoglobin at any time that could not be explained 
by active infection: ?X-53 ?1 
Patient X-43 consistently had no tumor and had 
low haptoglobin level except for one high level 
at the time of an obvious upper respiratory 
infection. 
Patient X-53 developed an elevated haptoglobin at 
the time of writing but did not yet have any 
sign of tumor recurrence. 
t 
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In summary, the total number of natients followed serially 
was 35. The number of patients with tumor mass >6cm. who 
failed to develop an elevated haptoglobin level at anv time was 
1 (X-18)^ The number of patients who had tumor mass > 6 cm. and 
who did develop an elevated haptoglobin at least once but who 
for the most part of this study had normal haptoglobins was 1 
(X-19). The number of patients with tumor mass < 6 cm. who had 
normal haptoglobin levels for most of the study but whose hapto¬ 
globin rose to abnormal level which could not be explained by 
infection or recurrence of widespread tumor was ?1 (?X-53). 
There was one patient with tumor mass < 6 cm. who had elevated 
haptoglobin levels over A months prior to physical evidence of 
recurrence. 
The total number of negative correlations between amount 
of tumor and level of haptoglobin was 2: 
Tumor > 6 cm. with normal haptoglobin level 
for most of the time of this study: 2 
(X-18, X-19) 
Tumor < 6 cm. with elevated haptoglobin level 
for most of the time of this study: 0 
The total number of positive correlations was 33. 
Tumor > 6 cm. with elevated haptoglobin level 
for most of the time of this study or tumor 
< 6 cm. with normal haptoglobin level for 
most of this study. 
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DISCUSSION AND CONCLUSIONS 
Types of Haptoglobin 
1. There is no difference between the distribution of 
hantoglobin types in patients with malignant ovarian 
tumors and the distribution of hantoglobin types in the 
controls (p > .70). 
2. There is no difference between the distribution of 
types in patients with ovarian carcinomas and the 
distribution in controls (p > . 95). 
3. There is probably no difference between the distribution 
of hantoglobin types in patients with granulosa-thecal 
cell tumors, malignant teratomas, and embryonal cell 
tumors and the distribution of controls, but the number 
of patients was to small to state this with certainty. 
4. There is no difference between the distribution of 
haptoglobin types in patients with mucin producing adeno¬ 
carcinomas and the distribution in patients with non¬ 
mucin producing adenocarcinomas (p > .50). 
5. There is no difference between the distribution of 
haptoglobin types in patients with differentiated ovarian 
carcinomas and the distribution in patients with poorlv 
differentiated adenocarcinomas (p > .70). 
Genetic hantoglobin types do not appear to be related to malignant 
ovarian tumors in general, to any specific, type of ovarian tumor, to 
mucin production bv tumor, or to the degree of anaplasia of tumor. 
# 
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Amount of Haptoglobin - Single Determinations of Haptoglobin 
Quantity. 
1. Grossly elevated haptoglobin levels (i.e. levels of 
190 mg.% and above) seen in patients with ovarian 
tumor mass > 6 cm. in diameter are highly significant 
when compared to controls (p <.001). 
2. The gross elevations in serum haptoglobins in patients 
who died from ovarian malignancy within two months of 
the date of obtaining the serum are highly significant 
compared to controls (p < .001). 
3. In patients with a previous history of malignant ovarian 
tumor but no present physical, radiological, or surgical 
evidence of tumor, haptoglobin levels are not elevated 
when compared to controls (p = .77), 
4. In patients with tumor mass < 6 cm. haptoglobin levels 
are not grossly elevated when compared to controls 
(p = -77). 
5. Patients with widespread (tumor mass > 6 cm.)granulosa- 
thecal cell tumors or widespread embryonal cell tumors 
possibly may have considerably larger concentrations of 
haptoglobins than patients with widespread carcinomas, 
but the number of patients with these rare tumors was 
too few to allow the results to be significant. 
6. In patients with widespread tumor, haptoglobin levels 
probably are not influenced by the presence or absence 
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of mucin production. Again, the number of patients was 
too small to state this conclusion unequivicallv. 
7. In patients with widespread tumor, the degree of 
differentiation of the tumor does not influence the 
haptoglobin level ( p > .05). 
8. In patients with widespread tumor the use of radiotherapy 
or chemotherapy within two months prior to the obtaining 
of the serum sample has no effect upon haptoglobin level 
(p > .05). 
9. In patients with widespread tumor, laporotomv within 
2 months of the obtaining of the serum sample significantly 
raises the average haptoglobin approximately 23 mg.% 
(from 268 to 291) (.01 < p < .05). 
Amount of Haptoglobin - Serial Determinations of Haptoglobin 
Quantity - 
1. In 94.3% of the patients with malignant ovarian tumors 
(33 out of 35 patients) serum haptoglobin levels correlate 
with the amount of tumor mass: 
< 6 cm. mass yields normal haptoglobin levels 
> 6 cm. mass yields elevated haptoglobin levels 
A decrease in tumor mass to < 6 cm. is accompanied bv 
a decrease from abnormally high haptoglobin levels to 
normal levels. With successful chemo- or radio-therapy. 
this decrease may precede clear physical or radiologic 
I 
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evidence of decreasing tumor size. (Of the 7 patients 
whose tumor was completely removed, none had elevated 
haptoglobin levels that remained elevated.) 
3. An increase intumor mass to > 6 cm. is accompanied 
by an increase in haptoglobin from normal to high 
levels. This increase in haptoglobin levels mav 
precede clear physical or radiologic evidence of 
increasing tumor mass. (25 out of 26 patients with 
widespread tumor developed high haptoglobin levels.) 
4. A single isolated normal haptoglobin level in the presence 
of widespread tumor is not significant. (3 out of 19 
patients with continued widespread tumor showed transient 
normal levels. 1 out of 19 patients with continued 
widespread tumor showed a drop to a normal level which 
persisted. 1 out of 19 patients with continued widespread 
tumor showed no elevation in haptoglobin.) 
5. A single high haptoglobin unexplained by intercurrent 
infection or other diseases which cause elevated hapto¬ 
globin is a probable indication of recurrent tumor. 
(Only 1 of 9 patients with continued evidence of tumor 
mass ^ 6 cm. developed an elevated haptoglobin.) Addendum: 
two weeks after the studv was concluded the patient 
developed ascites due to recurrent tumor. 
Possible Pathophysiological Mechanisms of Increased Haptoglobin 
Production with Widespread Ovarian Tumor 
How do ovarian tumor with tumor mass $ 6 cm. cause 
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elevation in serum haptoglobin levels? Theoretically there are 
three possible mechanisms for increased levels: 
1) Increased synthesis by liver and/or synthesis by another 
organ 
2) Increased release of stored haptoglobin 
3) Decreased uptake or removal of haptoglobins 
Studies of patients with Hodgkin’s tumor show that the rate of 
clearance of haptoglobin from the blood stream is directly nropor- 
tional to the total amount of haptoglobin in the blood stream (i.e. 
3132 
the fractional removal rate is constant). ’ If this conclusion 
holds true for patients with ovarian carcinomas as well, decreased 
uptake of haptoglobins does not occur? there is no naralysis of 
the reticulo-endothelial system,and possibility 3) above is eliminated. 
Release of stored haptoglobin might explain the elevations in 
serum haptoglobin following surgery. However, the elevation of 
serum haptoglobins seen in some patients with continued widespread 
tumor went on for extended time periods: patient X—15, for instance, 
had a marked elevation for seven months. There would have to be 
enormous depot stores of haptoglobin if increased release of pre¬ 
viously synthesized stores is to account for continued as well as 
transient elevations; for the turnover rate of haptoglobin is 
relatively short - approximately four davs. Thus, possibility 2) 
seems an unlikely explanation for long-standing elevations. 
Only possibility 1) is left: increased synthesis of hapto¬ 
globin by the liver parenchyma or by other tissue. Tt is possible 
that in the process dedifferentiation previously repressed operators 
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could be derepressed to dictate the synthesis of haptoglobin. 
However, haptoglobin is not a simple polypeptide but a complex 
molecule with alpha and beta chains joined in a specific manner 
and linked between beta and alpha2 chains to form polymers. It is 
unlikely that a dedifferentiated cell of a cell line which was 
originally incapable of producing haptoglobin would be able to 
produce such a complicated molecule. These ideas should, however, 
be validated experimentally with anti-haptoglobin antibody studies 
of normal and malignant ovarian tissue. 
The most likely explanation is that tumor causes an alteration 
in the serum which stimulates the liver to increased synthesis 
of haptoglobins. This change could be a hantoglobin stimulator 
substance produced by tumor growth or tumor breakdown as suggested 
by Graf and Probst.^3 
There appears to be a gradient in haptoglobin levels in 
relation to amount of tumor: 
No. of Average 
"Patients Haptoglobin Level 
C controls 
Patients with no evidence of tumor 
Patients with tumor < 6 cm. 









This gradient could best be explained byahantoglobin stimulating 
factor produced by tumor or tumor necrosis. 
Alternately, a haptoglobin stimulator substance could be produced 
by another organ, other than tumor tissue. An unanswered question 
is whether the increased synthesis of haptoglobin bv the liver in 
patients with large amount of malignant tumor is mediated bv the 
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adrendals. It is well known that androgen therapy raises 
haptoglobin levels and that androgen produced by the adrenals is 
converted to estrogen by the ovaries. Virilizing effects 
suggestive of increased androgen levels were not seen in these 
patients with ovarian tumors, but androgens might still be 
implicated in increased haptoglobin synthesis. Another possible 
mechanism involving the adrenal is that tumor causes a stress 
response with increased release of glucocorticoids and epinephrine 
which in turn stimulate the liver to produce haptoglobin. 
In conclusion, the most likely mechanism of increased 
haptoglobin levels in patients with malignant tumors appears to 
be increased synthesis by the liver, stimulated by a haptoglobin 
stimulator substance from adrenal or from tumor. The patho¬ 
physiology of increased serum haptoglobins is an important field 
for new exploration. 
Clinical Value of Haptoglobin Studies in Malignant Ovarian Tumois 
Haptoglobin types appear to be unrelated to ovarian malignancies 
and therefore are of no clinical value. 
A hemoglobin binding capacity of 190 mg./100ml. serum is a 
dividing line between grossly normal and grossly elevated hapto¬ 
globin levels. Variations in haptoglobin level which do not cross 
the 190 mg.% boundary line have as yet no discernible clinical 
significance. 
Haptoglobin levels do not appear to be influenced bv the 
type of ovarian malignancy. The results suggest that widespread 
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granulosa-theca cell tumors and embryonal cell tumors are 
associated with especially high haptoglobin levels , > 300mg.%, 
but a larger number of patients should be studied to reach a 
definite conclusion. Furthermore, haptoglobin levels do not 
appear to be influenced by the degree of anaplasia of the tumor or 
by mucin production. 
Haptoglobin levels are definitely affected bv the amount of 
tumor present. Because they are minimally affected bv the tvne 
of ovarian tumor or by chemotherapy, radiotherapy, or surgerv per 
se they are of value in indicating the amount of tumor irrespective 
of therapy or tumor type. 
Although an isolated normal haptoglobin determination (<190mg. 
is not of value in determining the amount of tumor, continued normal 
haptoglobin levels in the vast majority of cases indicate that tumor 
mass is < 6 cm. and that radio-, chemo-, and surgical therapv have 
been effective in containing the tumor. However, continued normal 
haptoglobin levels of themselves are not conclusive evidence that 
tumor remains < 6 cm. 
An isolated elevated haptoglobin level which cannot be 
explained by infection or other disease known to cause elevation 
is very strongly suggestive of tumor > 6 cm: tumor has recurred, 
or previously existing tumor is failing to respond to radio-, chemo- 
or surgical therapy. Continued elevated haptoglobins imply 
continued existence of tumor >6cm. 
A decrease of haptoglobin level from > 190 mg.% to • 190 mg.% 
followed by continued normal haptoglobin levels implies successful 
therapy. An increase of haptoglobin level from < 190 mg.% to 
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> 190 mg.% in the absence of infection, etc., is strongly suggestive 
of tumor mass increasing to < 6 cm. and of recurrence of tumor. 
Decreases and increases in haptoglobin levels may precede the 
clinical evidence of decreasing or increasing tumor: an unexplained 
increase in haptoglobin from. < 190 mg.% to > 190 mg.% is an earlv 
indication of tumor recurrence. 

SUMMARY 
Sera of 58 pat ients with ovarian cancers were typed and 
quantified for haptoglobins. The relationships between hapto¬ 
globin type and tumor type, mucin production and the degree 
of differentiation were investigated. The relationships 
between haptoglobin level and tumor type, amount of tumor, 
death from tumor, mucin production, degree of differentiation, 
recent radio-, chemo- and surgical therapv were also investi¬ 
gated. 35 patients were followed with serial haptoglobin 
levels. In addition to haptoglobin level, the amount of tumor, 
use of radiotherapy5chemotherapy, and surgery, and the occurence 
of death were noted. The study posed some interesting questions 
concerning the pathophysiology of increased haptoglobin levels 
seen with ovarian cancers and with other conditions. The results 
and conclusions suggest that haptoglobin levels either in single 
instances or serial studies may be of clinical value in following 
the course of malignant ovarian tumors and in suggesting tumor 













D-l P.S. 2-1 60 
D-2 K.P. 2-2 38 
D-3 E.DeS. 2-1 40 
D-4 A.M. 2-1 110 
D-5 G.W. 1-1 80 
D-6 P.H. 2-1 120 
D-7 J.C. 2-1 42 
D-8 B.P. 1-1 72 
D-9 W.M. 1-1 58 
D-10 E.W. 2-2 20 
D-ll K.B. 2-1 90 
D-l 2 C.D. 2-2 150 
D-l 3 D.W. 2-2 136 
D-l 4 M.H. 2-1 60 
D-15 T.G. 1-1 72 
D-l 6 B.P. 1-1 66 
D-17 S. A. 2-1 170 
D-18 J.V. 1-1 38 
D-19 C. A. 2-1 162 
D-20 C.Y. 1-1 38 
D-21 S.Q. 1-1 76 













D-25 E. A. 





























C-l G.K. A2-59-59 39 06/30/69 Menorrhagia 2-2 56 
C-2 U.M. 43-11-44 41 06/30/69 Uterine leiomyoma 2-1 67 
C-3 L.C. 75-38-35 36 06/30/69 Anovulatory bleed 2-1 58 
C-4 L.L. 61-19-66 30 06/30/69 Venous varicosities 2-1 44 
C-5 H. A. 41-99-96 44 07/02/69 Menorrhagia 2-2 59 
C-6 H.B. 74-94-31 24 07/02/69 Bartholin cyst 1-1 128 
C-7 D.F. AO-61-84 72 07/02/69 Vaginal band 2-2 38 
C-8 M.H. 73-80-85 39 07/02/69 Deviated septum 2-2 26 
C-9 B.J. 33-02-98 42 02/17/70 Hemorrhoids 2-2 92 
C-10 P .W. 39-83-75 45 07/02/69 Uterine leiomyoma 2-2 65 
C-ll V. I. 31-65-67 49 07/02/69 Uterine leiomyoma 2-2 69 
C-l 2 M.B. 54-90-27 50 07/03/69 Menopause 2-1 128 
C-l 3 A.M. 60-54-90 53 07/03/69 Inguinal hernias, 
diverticulosis,leiomyoma 
2-1 102 
C-14 M.F. 36-84-48 48 07/01/69 Chronic cystic mastitis 2-1 92 
C-15 C.W. 42-21-22 43 07/03/69 Cervical polyp-Class I, 
uterine leiomyoma 
2-1 88 
C-16 T.S. C3-61-74 62 07/07/69 Hemorrhoids 2-1 103 
C-l 7 J.M. 60-79-27 38 07/07/69 Elective tubal ligation 2-1 112 
C-18 E. S . 75-45-57 55 07/07/69 Endometriosis 2-1 39 
C-l 9 R.M. 68-21-08 30 07/08/69 Chronic cystic mastitis 2-2 36 
C-20 A.Z . 75-45-88 23 07/08/69 Bunion 2-1 38 
C-21 S.L. 75-45-89 51 07/08/69 Disuse atrophy of meniscus 2-1 52 
C-2 2 B.M. 36-79-98 68 07/08/69 Enterocele 2-1 60 
C-23 A. E . B6-07-15 24 07/08/69 Chronic cystic mastitis 2-1 62 
C-24 L.B. 75-40-91 54 07/08/69 Menorrhagia 1-1 100 












C-26 T.K. 64-85-66 37 07/09/69 Uterine prolapse 2-1 44 
C-27 P.M. 71-88-73 23 07/09/69 Benign laryngeal cyst 2-1 42 
C-28 M.M. 06-92-99 42 07/09/69 Venous varicosities 2-2 128 
C-29 R.M. 63-45-95 27 07/09/69 Hemorrhoids 2-1 76 
C-30 J.W. 57-21-39 43 07/09/69 Anovulatory bleed 2-2 40 
C-31 V.V. 75-46-17 51 07/10/69 Bunions 2-1 126 
C-32 M.K. 37-14-13 53 07/10/69 Hemorrhoids,anal fissure 2-2 230 
C-33 M.H. C3-74-99 56 07/10/69 Chronic pelvic inflammatory2-l 156 
disease 
C-34 F.E. 75-46-41 51 07/10/69 Essential hypertension 2-2 84 
C-35 M.M. B2-79-76 59 07/10/69 Ganglion 2-1 112 
C-36 N.M. 52-13-86 49 07/10/69 Fibroadenoma of breast 2-1 134 
C-37 M.S. 42-97-97 43 07/11/69 Herniated disk 2-2 38 
C-38 M.V. C3-32-96 43 07/11/69 Uterine leiomyomata 2-2 168 
C-39 H.F. Al-32-15 43 07/11/69 Uterine prolapse 2-2 34 
C-40 C.F. 45-38-17 45 07/11/69 Hemorrhoids,anal fissure 2-2 68 
C-41 D.S. 69-28-61 27 o7/ll/69 Venous varicosities 1-1 84 
C-42 N.M. 72-76-67 39 07/14/69 Benign endometrial polyp 1-1 76 
C-43 M.B. 02-87-82 46 07/14/69 Hemorrhoids 2-2 148 
C-44 D.H. 47-45-89 31 07/14/69 Carcinoma in situ of cervixl-1 94 
C-45 J.B. 48-73-96 48 07/17/69 Venous varicosities 2-1 52 
C-46 F.W. 08-88-81 48 07/17/69 Scar and neuroma 2-2 132 
C-47 M.H. Bl-08-43 52 07/17/69 Uterine leimyoma 2-2 68 
C-48 E. J. 49-12-08 33 07/17/69 Benign breast cyst 2-1 6 8 
C-49 C.H. 75-54-99 44 07/17/69 Chronic cystic mastitis 2-1 30 
C-50 J.S. 77-32-34 31 02/17/70 Tubal adhesions 2-1 40 
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PATIENTS WITH MALIGNANT OVARIAN TUMORS 
Study Init. Hospital Age Date Radio- Chemotherapy Surgery 
// Unit # therapy 
1* 2* 3* 1* 2* 3* 1* 2* 3* 
X-l M.P. 52-02-92 62 08/20/68 0 + 0 0 0 0 0 0 
X-2 A.D'E .46-55-58 41 08/12/68 0 + 0 0 A B 0 + 0 
X-3 E.S . 68-10-16 48 09/05/68 0 0 0 0 A B 4* 0 0 
X-4 B.F. 38-93-67 46 09/05/68 0 + 0 0 A A 0 + 0 
X-7 L. A. 71-08-07 42 09/17/68 0 + 0 0 A B 0 + 0 
X-8 B.H. 71-24-03 47 09/13/68 0 + 0 0 0 A + 0 0 
X-9 L.H. 59-55-08 51 02/04/69 0 0 0 0 0 0 0 0 0 
X-ll J.S. 72-48-63 57 09/09/68 0 0 + 0 0 A 0 + 0 
X-l 2 A.P. B0-52-13 47 02/04/69 + 0 0 A A A + 0 0 
X-l 3 L.S. 72-41-43 50 02/06/69 0 + 0 0 A A 0 + 0 
X-l 4 R.H. A3-06-98 61 02/05/69 0 + 0 0 A A 0 + 0 
X-15 J.C. 72-24-51 42 02/04/69 0 + 0 0 A A 0 “f* 0 
X-16 B.M. 73-67-76 42 02/04/69 0 0 + 0 0 0 0 + 0 
X-17 R.C. 73-93-73 43 02/12/69 0 0 0 0 0 A 0 0 + 
X-18 F.L. 71-33-64 56 09/01/68 0 + 0 0 0 A 0 + 0 
X-19 A.H. Cl-08-75 56 07/23/69 0 0 0 A A A + 0 0 
X-20 M.P. B4-20-43 59 02/11/69 0 0 0 0 A A 0 + 0 
X-21 P.P. 73-58-61 55 02/04/69 0 0 0 0 0 A 0 + 0 
*1. 1 Within 5 years to 1 year prior to date of serum sample 
2. i Within 1 year to 2 months prior to date of serum sample 
3. Within the two months predeing the date of the serum sample 
Chemotherapy symbols: 
0: no chemotherapy 
A: uracil mustard and 5-fluorouracil 




Study Tissue Mucin Hap. Amount Evidence Hbg, Hbg. Binding 




X-l Au 0 2-2 2 P.E. 256 256 
X-2 Ad 0 2-1 2 P.E. 176 176 
X-3 G 0 2-1 2 P.E.,autopsy 440 440 
X-4 Ad 0 2-1 2 P.E. 228 228 
X-7 Au 0 2-1 2 X-ray 282 282 
X-8 Ad 0 2-2 2 Laporotomy 196 - 
X-9 Ad 0 2-1 2 P.E. 416 - 
X-ll Ad 0 2-1 2 P.E. 208 208 
X-l 2 Ad 0 2-1 0 Autopsy 156 - 
X-l 3 Au + 2-1 0 P.E.,X-ray 180 - 
X-14 Ad 0 2-2 0 P.E.,X-ray 68 - 
X-15 Ad 0 2-1 1 P.E.: breast 
ca.-l„5 cm. 
120 - 
X-16 Ad 0 1-1 0 P.E.,X-ray 124 - 
X-l 7 Au 0 1-1 2 Laporotomy 154 - 
X-18 Au 0 2-2 0 P.E. 160 - 
X-19 Ad 0 2-2 0 P.E. 138 no 
X-20 Ad 0 2-1 1 P.E. 76 262 
X-21 Ad 0 2-1 2 P.E. 120 - 
^Tissue diagnosis: Ad: Differentiated adenocarcinomas , including 
papillary, serous,cystic, and mucinous 
adenocarcinomas and combinations thereof 
Au: Undifferentiated adenocarcinomas 
G: Granulosa-theca cell tumors 
T: Malignant teratomas 
E: Embryonal cell tumors 
0: No evidence of tumor 
1: Evidence of tumor <6cm. in diameter 
2: Evidence of tumor >6cm. in diameter 
*** Last hbg. binding capacity determination before expiration: 
date of serum sample was within two months of 
date of death from tumor 
** Amount tumor 
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Study Init. Hospital Age Date Radio- Chemotherapy Surgery 
# Unit # therapy 
1 2 3 1 2 3 1 2 3 
X-22 H.M. 73-66-76 38 03/10/69 0 0 0 0 A 0 4- 0 
X-23 R.W. 73-99-57 47 02/04/69 0 0 + 0 0 0 0 4- 0 
X-25 M.L. A4-78-68 62 05/28/69 0 0 0 0 0 0 0 0 0 
X-26 A. S. B4-75-36 52 03/17/69 0 0 0 0 0 A 0 4- 0 
X-27 E. L. 74-70-23 66 06/16/69 0 0 4- 0 0 0 0 4- 0 
X-31 S.C. 74-32-29 62 06/12/69 0 4- 0 0 0 A 0 0 H" 
X- 32 J.D'A, .72-97-14 49 09/23/69 0 4- 0 A B B 4- 0 0 
X-33 M.P. 75-13-05 64 06/16/69 0 0 4- 0 0 0 0 0 4- 
X-34 A.G. 40-61-47 65 06/12/69 0 0 0 0 0 0 0 0 4- 
X-35 L. H. 70-06-03 65 03/04/69 4- 0 0 A A A 4- 0 0 
X-36 R.M. 67-74-35 74 02/17/69 + 0 0 A A A 4- 0 0 
X-38 A. J. 69-03-37 84 08/27/69 + 0 0 A 0 0 4- 0 0 
X-39 M.L. 75-89-56 51 08/29/69 0 0 0 0 0 0 0 0 4- 
X-40 B.C. 05-18-29 51 09/09/69 + 0 0 A B B 4- 0 0 
X-41 S.B. 65-14-06 45 06/20/69 4- 0 0 A 0 0 4- 0 0 
X-42 E.B. BO-85-31 69 01/07/70 0 0 0 0 0 A 0 4- 0 
X-43 A.M. 65-73-80 44 01/06/70 0 0 0 A B B 4- 0 0 
X-44 I.S, 49-82-95 70 10/06/69 0 0 0 0 0 0 0 0 4- 
X-45 D.R. C6-24-08 49 10/16/69 0 0 0 0 0 0 0 0 0 
X-46 M.C. C4-80-48 46 11/24/69 0 0 4- 0 0 0 0 0 4- 
X-47 E.B. C6-07-12 48 10/07/69 0 0 4- 0 0 A 0 0 ~i" 
X-48 R.S. 76-23-12 54 01/07/70 0 0 0 0 A A 0 4- 0 
X-49 M.D. Cl-86-78 53 11/20/69 0 0 0 0 0 A 0 0 4- 
X-50 C.C. 75-94-50 57 ll/2o/69 0 0 0 0 A A 0 4- 0 
X-5.1 S .P. 76-78-19 25 12/15/69 0 0 0 0 0 0 4- 0 4- 

















X-2 2 Ad 0 2-2 2 P.E. 116 116 
X-2 3 Ad 0 2-1 1 P.E. 102 - 
X-25 Ad 0 2-2 2 Laporotomy 212 - 
X-26 Ad + 2-2 2 Autopsy 272 272 
X-2 7 Ad 0 2-1 1 Laporotomy 180 - 
X- 31 Ad 0 2-1 2 P.E. 292 508 
X-32 Au 0 2-2 2 P.E. 180 256 
X-33 Au 0 2-1 2 P.E. 260 274 
X-34 Ad 0 2-1 2 Laporotomy 324 - 
X-35 Ad 0 2-2 0 P.E.,X-ray 74 - 
X-36 Ad 0 2-1 0 P.E.,X-ray 156 - 
X-38 Ad 0 2-1 0 P.E.,X-ray 108 - 
X-39 Au 0 2-2 1 P.E,,laporotomy!70 - 
X-40 Ad + 2-2 0 P.E.,X-ray 56 - 
X-41 Ad 0 2-1 0 P.E.,X-ray 110 - 
X-42 Au 0 2-1 2 P.E. 524 380 
X-4 3 Au 0 2-2 0 P.E.,X-ray 120 - 
X-44 Au 0 2-1 2 Laporotomy 290 - 
X-45 Ad 0 2-2 2 Laporotomy 154 220 
X-46 Au 0 2-2 2 Laporotomy 300 - 
X-4 7 Au 0 1-1 2 P.E.,X-ray 196 210 
X-48 Ad 0 1-1 2 P.E. 170 - 
X-49 Ad 0 2-1 1 P.E. 100 - 
X-50 Au 0 2-1 0 P.E. 104 - 
X-51 Ad + 2-1 2 Laporotomy 380 380 
X-53 Ad 0 2-2 0 P.E. 120 — 
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Study Init. Hospital Age Date Radio- Chemotherapy Surgery 
# Unit # therapy 
1 2 3 1 2 3 1 2 3 
X-55 J. J. 44-18-38 43 01/06/70 0 0 + 0 0 0 0 0 + 
X-56 S.G. 52-42-21 32 10/06/69 0 + 0 0 0 0 0 0 + 
X-57 M.McG .76-59-63 63 01/04/70 0 0 0 0 0 0 0 + 0 
X-58 D.S. 07-33-09 70 12/15/69 + 0 0 0 0 0 4* 0 0 
X-59 E.S . 76-84-73 44 12/16/69 0 0 0 0 0 0 0 0 + 
X-60 L.Z. 78-85-16 26 12/17/69 0 0 0 0 0 0 0 0 + 
X-61 E.B. 76-31-04 45 01/07/70 0 + 0 0 0 0 0 + 0 
X-62 V. B. 67-98-79 43 01/07/70 + 0 0 A A A + 0 0 
X-64 L.C. 75-76-12 73 01/14/70 0 0 0 0 0 0 0 0 0 
X-65 A.F. 47-68-72 67 01/14/70 0 0 0 0 0 A 0 0 + 
X-66 M.M. 66-51-38 65 01/14/70 + + 0 0 0 0 + 0 0 
X-68 S.C. 77-22-31 18 01/15/70 0 0 0 0 0 0 0 0 + 
X-69 H.M. 75-48-25 58 08/08/69 0 + 0 0 0 A 0 + 0 











Evidence Hbg, Hbg. Binding 
Binding Capacity 
Capacity at Death 
X-55 Ad 0 2-1 2 Laporotomy 410 - 
X-56 Ad 0 2-2 2 Laporotomy 396 - 
X-5 7 Au 0 2-1 2 P.E.,laporotomy270 240 
X-58 Au 0 2-2 1 P.E. 150 - 
X-59 Au + 2-1 1 P.E. 140 - 
X-60 T 0 2-1 2 Laporotomy 164 - 
X-61 Ad + 1-1 0 P.E. 188 - 
X-62 Ad 0 2-2 2 P.E. 360 - 
X-64 None - 2-2 2 P.E.,X-ray 200 - 
X-65 G 0 2-1 1 Laporotomy 160 - 
X-66 Ad 0 2-2 2 P.E. 110 - 
X-68 E 0 2-2 2 Laporotomy,1 ’.E.360 - 
X-69 Ad 0 2-1 2 P.E. 277 277 
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